LANGHORNE, Pa., March 30, 2026
Savara Inc. has achieved a major regulatory milestone as the European Medicines Agency (EMA) validated its Marketing Authorization Application (MAA) for MOLBREEVI, a novel therapy targeting autoimmune pulmonary alveolar proteinosis (PAP), marking a critical step toward addressing a rare and debilitating respiratory condition with limited treatment options.
Regulatory Momentum Strengthens Global Strategy
The EMA validation confirms that Savara’s submission is complete and ready for formal scientific review by the Committee for Medicinal Products for Human Use (CHMP). This milestone officially initiates the European review process, with a regulatory decision anticipated in Q1 2027, positioning MOLBREEVI as a potential first-in-class therapy in Europe for autoimmune PAP. In parallel, the therapy is already under Priority Review by the U.S. Food and Drug Administration, with a targeted action date of August 22, 2026, further emphasizing the strong global regulatory momentum behind the program.
Additionally, Savara has expanded its international strategy by submitting the MAA to the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA), reinforcing its commitment to broad geographic access and accelerated commercialization pathways. The therapy has also received multiple prestigious designations, including Orphan Drug, Fast Track, and Breakthrough Therapy, highlighting both the urgent unmet medical need and the drug’s transformative potential.
Innovative Approach to Treat Autoimmune PAP
Advertisement
MOLBREEVI (molgramostim inhalation solution) represents a cutting-edge biologic therapy designed to directly address the underlying cause of autoimmune PAP. This rare lung disorder is characterized by the accumulation of surfactant within the alveoli, impairing oxygen exchange and leading to symptoms such as shortness of breath, fatigue, and chronic cough.
The condition arises due to autoantibodies that neutralize granulocyte-macrophage colony-stimulating factor (GM-CSF), a critical protein required for immune cells to clear excess surfactant. MOLBREEVI works by replacing GM-CSF activity, restoring the function of alveolar macrophages and enabling the lungs to clear accumulated material more effectively.
Delivered באמצעות an inhalation-based nebulizer system, the therapy offers a targeted, localized treatment approach, potentially improving both efficacy and safety compared to systemic therapies. If approved, MOLBREEVI could become the first specifically indicated therapy for autoimmune PAP, fundamentally transforming how this chronic and progressive disease is managed.
Addressing a Critical Unmet Medical Need
Autoimmune PAP remains a rare but serious pulmonary condition, often requiring invasive procedures such as whole lung lavage to manage symptoms. Despite advances in respiratory medicine, there are currently no approved pharmacological treatments specifically targeting the root cause of the disease in major global markets. This creates a significant burden on patients, who may experience progressive respiratory decline, recurrent infections, and long-term complications including lung fibrosis or transplantation.
Savara’s MOLBREEVI has the potential to shift the treatment paradigm by offering a disease-modifying therapy rather than symptomatic relief. The company’s leadership emphasized that this milestone represents a pivotal advancement in its regulatory strategy, bringing the therapy closer to patients who urgently need more effective and less invasive options. With strong clinical development progress and robust regulatory engagement, Savara is positioning itself at the forefront of rare respiratory disease innovation, with MOLBREEVI serving as its flagship program
As regulatory reviews progress across the U.S., Europe, and the U.K., industry stakeholders and clinicians are closely monitoring developments, given the therapy’s potential to redefine standards of care in autoimmune PAP. If successful, MOLBREEVI could not only become a first-in-class treatment but also set a precedent for future targeted biologics in rare pulmonary diseases, reinforcing the growing importance of precision medicine in addressing complex immune-mediated conditions.
Source: Savara Inc press release
